Overview Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia Status: Completed Trial end date: 2002-02-01 Target enrollment: Participant gender: Summary Study of efficacy & safety of oral YM087 in subjects with euvolemic or hypervolemic hyponatremia Phase: Phase 3 Details Lead Sponsor: Cumberland PharmaceuticalsCollaborator: Parke-DavisTreatments: Conivaptan